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ABSTRACT
Site-specificmodificationoftheN1-positionofpurine
was explored at the nucleoside and oligomer levels.
20-Deoxyinosine was converted into an N1-2,4-
dinitrophenyl derivative 2 that was readily trans-
formedtothedesired N1-substituted 20-deoxyinosine
analogues.Thisapproachwasusedtodevelopapost-
synthetic method for the modification of the endo-
cyclic N1-position of purine at the oligomer level.
The phosphoramidite monomer of N1-(2,4-dinitro-
phenyl)-20-deoxyinosine 9 was prepared from 20-
deoxyinosine in four steps and incorporated into
oligomers using an automated DNA synthesizer.
The modified base, N1-(2,4-dinitrophenyl)-
hypoxanthine, in synthesized oligomers, upon treat-
ment with respective agents, was converted into
corresponding N1-substituted hypoxanthines, includ-
ing N1-
15N-hypoxanthine, N1-methylhypoxanthine
andN1-(2-aminoethyl)-hypoxanthine.Thesemodified
oligomers can be easily separated and high purity
oligomers obtained. Melting curve studies show the
oligomer containing N1-methylhypoxanthine or
N1-(2-aminoethyl)-hypoxanthine has a reduced ther-
mostability with no particular pairing preference to
either cytosine or thymine. The developed method
could be adapted for the preparation of oligomers
containing mutagenicN1-b-hydroxyalkyl-hypoxanth-
ines and the availability of the rare base-modified
oligomers should offer novel tools for biological
and structural studies.
INTRODUCTION
Maintenance of the structural integrity of DNA is essential for
the existence and continuation of any species. However, the
various components of DNA (bases, sugars and phosphodi-
esters) are highly susceptible to damage from both internal
(e.g. enzymatic hydrolysis) and external sources (e.g. indus-
trial pollutants). Damaged DNA, if left unrepaired, can result
in serious consequences, such as gene mutation, cell death and
even cancer (1,2). Among the various types of damage, base
modiﬁcation is of central importance, as the genetic informa-
tion is encoded in the bases. In order to study the consequences
of DNA base damage and repair at the molecular level, one
must have the required base-modiﬁed DNA. In general, there
are two routes to achieve this: (i) by isolation of the modiﬁed
DNA from a biological system or (ii) by chemical synthesis of
modiﬁed oligomers. The latter is the method of choice since
the chemical synthesis approach can not only supply sufﬁcient
amount of base-modiﬁed oligomers but also offer unique
access to DNA sequences with base modiﬁcations at prede-
termined positions.
There is an ongoing search for better approaches to the
chemical synthesis of oligomers containing modiﬁed bases
(3). The conventional approach involves the preparation of
the required base-modiﬁed monomer (usually as a phosphor-
amidite derivative) followed by incorporation of the monomer
into oligomers using a DNA synthesizer (4). This approach is
best for the preparation of DNA containing stable modiﬁed
bases, as the modiﬁed base and other DNA building blocks
have to be subjected to various treatments, such as repeated
capping and oxidation during DNA synthesis and alkaline
deblocking after synthesis. However, in many cases, a modi-
ﬁed base of biological interest is not stable enough to survive
such conditions. To overcome this problem, post-synthetic
substitution approaches have been developed by our group
(5–8) and others (3,9–12). The common features in these
approaches are (i) preparation of a versatile monomer contain-
ing a suitable leaving group on the base; (ii) incorporation of
the monomer into oligomers; and (iii) replacement of the
leaving group after DNA synthesis. The leaving group in
the versatile monomer should be stable during DNA synthesis
and subsequent deblocking and convertible by other chemicals
to introduce the required functional group on the base after
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advantages over the conventional approach. For example, the
synthesis of a single oligomer containing a versatile base
provides the source of different oligomers each containing a
different modiﬁed base. Expensive isotopes, such as
15N, can
be cost-effectively introduced onto the speciﬁed base by
treatment with appropriate reagents in the ﬁnal step (13,14).
Such site-speciﬁc
15N labelling at the oligomer level can be
viewed as a complementary approach with those used for
initial synthesis of
15N-labelled nucleosides and subsequent
preparation of labelled DNA (15,16).
The post-synthetic approach has been applied primarily to
the modiﬁcation of exocyclic positions, such as the 4-position
of pyrimidines (5,6,9–11) or the 6-position of purines (7,8) or
the 2-positionof guanine(12).These positions are biologically
important as they are directly involved in hydrogen bonding
associated with DNA base pairings. Modiﬁcations of endo-
cyclic positions require ring-opening and re-closure that
are more complicated and challenging. To the best of our
knowledge, no post-synthetic approach has been used to
modify endocyclic positions at the oligomer level. The endo-
cyclic positions that are directly involved in Watson–Crick
hydrogen bonding are the N1-position of purines (adenine,
guanine or hypoxanthine) and the N3-position of pyrimidines
(thymine and cytosine). Obviously, any modiﬁcation of
these endocyclic positions would produce bases of varied
pairing properties and such base-modiﬁed DNA would
certainly offer interesting properties useful for DNA-related
studies.
20-Deoxyinosine (the deoxynucleoside of hypoxanthine) is
the deamination product from 20-deoxyadenosine. Recent
studies suggested that N1-b-hydroxylalkyl-hypoxanthine in
DNA, arising from the reaction of adenine with simple epox-
ides (such as ethylene oxide, 3,4-epoxy-1-butene and styrene
oxide) and subsequent deamination, plays an important role in
mutagenesis and carcinogenesis induced by these epoxides
(17–19). Synthetic methods for oligomers having such
N1-substituted hypoxanthine are required in order to establish
the biological effects of the lesions. A method (19) has been
recently developed for the synthesis of oligomers containing
N1-adducted-hypoxanthine, in which 4-acetoxy-3-bromo-1-
butene (the equivalent reagent for 3,4-epoxy-1-butene) was
reacted with 30,50-protected deoxyinosine to prepare N1-
substituted nucleoside. Owing to diverse activities of the
reagent (reacting at C1- or C3-position) and various nucleo-
philic sites of the nucleoside (such as N1- and O
6-positions),
multiple products were formed. Thus, the target nucleosides
were obtained in low yield (33%) and were irresolvable
mixtures of diastereomers. Obviously, a better method
is still required. With this in mind, we have therefore
undertaken the challenge to modify the endocyclic N1-
position of deoxyinosine by a post-synthetic approach. Here,
we report (i) the transformations of N1-(2,4-dinitrophenyl)-20-
deoxyinosine 2 into various desired nucleosides; and (ii) the
preparation of a versatile phosphoramidite monomer 9, its
incorporation into oligomers and the conversion of the incor-
porated versatile base into various modiﬁed bases, including
N1-
15N-labelled hypoxanthine3asa NMR probe forstructural
studies, N1-methylhypoxanthine 4 as a novel base for muta-
genic investigation, N1-(2-aminoethyl)-hypoxanthine 5 as a
reactive group for site-speciﬁc cross-linking. It is envisaged
that the developed method is adaptable to prepare oligomers
containing other N1-substituted hypoxanthines (including
hypoxanthines adducted by the above-mentioned epoxides)
and that the availability of these base-modiﬁed oligomers
will permit an exploration of their structural and biological
properties.
RESULTS AND DISCUSSION
Synthetic exploitation of versatile
N1-DNP-20-deoxyinosine 2
In the search for a suitable approach for the direct modiﬁcation
of endocyclic positions in nucleosides or oligomers, it was
noted that N1-(4-nitrophenyl)- or N1-(2,4-dinitrophenyl)-20-
deoxyinosine could be converted to N1-substituted
20-deoxyinosine via nucleophilic substitution (20–22). We
have re-investigated this reaction with a view to its use
at the oligomer level. 20-Deoxyinosine 1 was reacted with
1-chloro-2,4-dinitrobenzene to form N1-(2,4-dinitrophenyl)-
20-deoxyinosine 2 in excellent yield. The introduced
2,4-dinitrophenyl (DNP) group serves not only as a strong
electron-withdrawing group to make the 2-position of
2 more susceptible to nucleophilic substitutions leading to
the ring-opening but also as part of the good leaving
group to facilitate the ring re-closure. We have exploited
this reaction to prepare various N1-modiﬁed nucleosides
(see Scheme 1).
Reaction of 2 with
15N-labelled ammonia afforded N1-
15N-
labelled 20-deoxyinosine 3. The isotopic difference between
1 and 3 was clearly demonstrated by the
1H NMR signals of
the proton at the 2-position (2H): in 3 it is a doublet
[
3J(N,H) = 7.2 Hz] as shown at the middle panel of Figure 1.
This splitting can only be attributed to the coupling of the 2H
with the neighbouring
15N-atom. Between the doublet (peaks a
and c) is a small resonance (peak b at 8.048 p.p.m.) that has the
same chemical shift as that of the 2H of 1 (Figure 1, top and
bottom panels). Integration of these three peaks (a, b and c)
gives an estimated ratio of 49:2:49 (a:b:c), suggesting that
 2% of unlabelled 20-deoxyinosine 1 is co-existent with the
product 3. The co-existence might arise from either, or both, of
the following sources: (i) cleavage of the DNP group of the
compound 2 by the alternative pathway as shown in Scheme 2
and (ii) isotopic impurity (
14N atom) in the labelling agent
(
15N ammonia). The isotopic purity of the labelling agent used
isquotedat98
+%andis,therefore,theprobablesourceofmost
of the unlabelled deoxyinosine. It seems safe to conclude that
the formation of the product 3 is almost exclusively via a
ring-opening and re-closure mechanism.
Reaction of 2 with methylamine produced N1-methylated
deoxyinosine 4. This novel treatment offers a facile synthetic
route to 4. In a recent paper (23), N1-methylated 20-deoxyin-
osine was prepared by reacting 20-deoxyinosine with diazo-
methane. The diazomethane reaction is non-speciﬁc, thus
produced both 4 and its isomer (O
6-methylated 20-deoxyin-
osine), making its puriﬁcation harder and its yield lower (only
48%). Our protocol presented above gave only the target com-
pound in almost quantitative yield. The ready reaction with
methylamine suggests that reacting 2 with other nucleophilic
alkylamines (e.g. ethylamine) should produce corresponding
N1-alkylated deoxyinosines.
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intermediate and can be converted to other modiﬁed
20-deoxyinosines by nucleophilic substitution. Besides simple
alkylamines, we have also used bi-functional agents. For
example, treated with ethylenediamine or hydroxylamine,
2 was readily transformed to the corresponding products:
N1-(2-aminoethyl)-20-deoxyinosine 5 or N1-hydroxy-20-
deoxyinosine 6, respectively. The protocol we developed
for 6 uses commercially available hydroxylamine (50%
aqueous solution at 55 C for 4 h) and is much simpler and
milder than one previously reported (NH2OH–HCl + KOH at
80 C for 4 h) (20). Clearly, our protocol offers an improved
method for the preparation of 6. In addition, 6 can be further
transformed, via simple ultraviolet (UV) irradiation, to
20-deoxyoxanosine 7 that is a known mutagenic product
obtained from the nitrosation of guanine in DNA (24). Fur-
thermore, all of the above-described modiﬁed nucleosides
can be well separated from the intermediate 2 by high-
performance liquid chromatography (HPLC) as shown in
Figure 2a, thus these modiﬁed nucleosides of high purity
can be made available.
The underlying chemistry for the conversion of 2 to other
nucleosides involves nucleophilic substitution; this is pre-
cisely that employed for the deprotection of synthesized oli-
gomers by ammonia. This realization prompted us to explore
a post-synthetic and site-speciﬁc modiﬁcation of the N1-
endocyclic position of hypoxanthine at the oligomer level.
For this purpose, we ﬁrst developed a synthetic route to the
phosphoramidite monomer of N1-dinitrophenyl-20-deoxyin-
osine 9, then incorporated it to DNA oligomers by automated
DNA synthesis and ﬁnally converted into the oligomers con-
taining various modiﬁed hypoxanthines.
Synthesis of N1-DNP-20-deoxyinosine phosphoramidite
monomer 9
The above-prepared N1-DNP-20-deoxyinosine 2 was trans-
formed to its phosphoramidite monomer 9 by standard trityla-
tion with DMT–Cl under basic conditions and subsequent
phosphitylation as shown in Scheme 3. Since it is the
ﬁrst report of this monomer, critical examinations were thus
performed to assess the monomer and to develop its use in
automated DNA synthesis.
Synthesis of oligomers containing versatile base
(N1-DNP-hypoxanthine)
Prior to synthesis. The stability of the monomer was ﬁrst
examined under DNA synthesis conditions. 30,50-Diacetyl-
N1-2,4-dinitrophenyl-20-deoxyinosine 10 was chosen as the
test compound since 10 is structurally similar to the versatile
monomer. Furthermore, with its hydroxyl groups being pro-
tected, 10 should behave chemically similar to the incorpor-
ated monomer in the oligomer. From various experiments,
we did not observe any detectable change with 10 after its
overnight treatment with each of the DNA synthesis
regents, including the deblocking solution (3% trichloro-
acetic acid in CH2Cl2), the activator solution (0.45 M
tetrazole in acetonitrile), the capping reagents (acetic
anhydride/N-methylimidazole) and the oxidation solution
(iodine/pyridine/water). The high stability of 10 under these
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Scheme 1. Preparation of N1-DNP-deoxyinosine and its conversions into other modified deoxynucleosides, DNP: 2,4-dinitrophenyl; dR: 20-deoxyribosyl.
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compatible with DNA synthesis.
During synthesis. Oligomers were synthesized by an auto-
mated DNA synthesizer using the manufacturer’s protocol
for b-cyanoethyl phosphoramidite chemistry (1 mmol scale).
The following modiﬁcations were made for optimum intro-
duction and coupling of the versatile phosphoramidite mono-
mer: (i) the monomer 9, once dissolved in the activator
solution (for enhanced mixing of the monomer and the activ-
ator), was immediately manually injected directly onto the
synthetic column to avoid the loss of the monomer in
the delivery line; and (ii) the coupling time of the versatile
monomer was increased to 5 min to offer sufﬁcient time for it
to be maximally incorporated into the oligomer. This modiﬁed
protocol resulted in satisfactory coupling yields for the ver-
satile monomer, mostly over 95%. No modiﬁcation was made
for the incorporation of normal monomers.
Post-synthetic conversion. The conversion requires the
following three steps: (i) cleavage of the synthetic oligomer
from its linked controlled porous glass (CPG) support; (ii)
removal of all the protecting groups from bases and
phosphates; and (iii) replacement of the N-DNP group on
the versatile base in the oligomer by a suitable agent to pro-
duce the desired base-modiﬁed oligomers as illustrated in
Scheme 4.
Inthe standard protocol,the cleavage ofsyntheticoligomers
from the support is commonly achieved by concentrated
(30 M) aqueous ammonia solution at room temperature
(RT) for half an hour. The linkage between the oligomer
and the CPG support is an acyl bond similar to the acetyl
bond in compound 10. We found the acetyl group in 10
was readily removed by various amines, including methylam-
ine, ethylenediamine, concentrated (30 M) and diluted (6 M)
aqueous ammonia solution, suggestingthat these amino agents
would be suitable to the cleavage of the oligomer.
In order to facilitate the removal of the protecting groups
from normal bases, we chose the use of a set of base-labile
monomers (Ultramild Monomers from Glen Research), in
which dA is protected with the phenoxyacetyl (PAC) group,
dG with the iso-propylphenoxyacetyl (iPr-PAC) group and dC
with the acetyl group. This set of protecting groups can be
readily removed by concentrated aqueous ammonia solution
within 2 h at RT or 15 min at 55 C.
The conversion of the versatile base to a modiﬁed base
within the synthesized oligomer is the most crucial step.
We have demonstrated that such conversion was achievable
at the nucleoside level (see Scheme 1). Here, we report that
such conversion can also be achieved at the oligomer level by
use of suitable amino agents, including methylamine, ethyle-
nediamine and diluted ammonia as shown in Scheme 4.
With aqueous ammonia solution (concentrated NH3, diluted
NH3 and dilute
15N-NH3). As discussed above, the production
of oligomer containing hypoxanthine involves the three steps:
cleavage, deprotection and replacement. As an example, we
synthesized a pentamer containing the versatile base [i.e.
AGXCT, X is the versatile base, N1-(2,4-dinitrophenyl)
hypoxanthine] and subjected it to concentrated aqueous
ammonia solution ( 30 M) for 24 h at RT, followed by puri-
ﬁcation by Nensorb cartridge. HPLC analysis of the oligomer
showed one major peak. The modiﬁed pentamer was further
puriﬁed by HPLC, and then digested with enzymes to its
component nucleosides. HPLC analysis of the enzymatic
digest showed ﬁve nucleoside peaks: 20-deoxycytidine (dC),
20-deoxyinosine (dI), 20-deoxyguanosine (dG), thymidine
(T) and 20-deoxyadenosine (dA), conﬁrming its correct
composition.
Our aim is to prepare an oligomer containing N1-
15N-
labelled hypoxanthine. However, the most concentrated
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Figure 1. Selected parts of NMR spectra of 1, 3 and their mixture which
demonstrate direct evidence that 3 has an
15N atom at its N1-position. Upper
panel: signals from normal deoxyinosine 1; middle panel: signals from 3
(
15N-labelled deoxyinosine); lower panel: signals from the mixture of 1 and
3 (equal ratio).
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15N-labelled ammonia solution is
5.9 M, a rather dilute solution. Therefore, we ﬁrst tested the
use of a 6 M ammonia solution at 55 C for 48 h. HPLC
analysis showed that the produced oligomer is the same as
that produced using the 30 M ammonia solution. Thus, we
used 5.9 M
15N-labelled ammonia solution for the post-
synthetic conversion of a synthesized pentamer (AGXCT).
After puriﬁcation and enzymatic digestion of the pentamer,
HPLC analysis gave ﬁve peaks corresponding to dC, dI, dG, T
and dA, indicating that the protocol was appropriate for the
preparation of
15N-lablled pentamer. We have used the same
protocol to make a nonamer (CCTGXGGAG, X: N1-
15N
hypoxanthine) for NMR studies.
With methylamine (MeNH2). Methylamine (aqueous solu-
tion) has been used as an effective cleaving and deprotecting
agent for DNA synthesis (25,26) but has not been tested as a
replacement agent for the N1-DNP group at the oligomer
level. In Scheme 1, we demonstrated that N1-DNP-20-
deoxyinosine 2 could be converted into N1-methyl-20-
deoxyinosine 4 by use of methylamine (40% aqueous
solution). Thus, the synthetic pentamer AGXCT was treated
with aqueous methylamine solution. After isolation and puri-
ﬁcation, the major peak was enzymatically digested to its
nucleoside composition. HPLC analysis of the digest showed
N1-methylated deoxyinosine as well as the four standard
deoxynucleosides. We have also prepared some longer
oligomers (e.g. 11mer) containing N1-methylated hypoxanth-
ineusingthesameprotocol andexaminedtheir thermostability
when paired with cytosine or thymine (see Table 1).
Oligodeoxynucleotides containing N-methylated hypoxanth-
ine have been recently prepared using a conventional approach
(23), in which N1-methylated 20-deoxyinosine was ﬁrst syn-
thesized and then transformed to its phosphoramidite that was
ﬁnally incorporated into oligomers. Obviously, our protocol
for oligomers containing N1-methylated hypoxanthine is
much simpler and could be readily adapted for the preparation
of oligomers containing other N1-alkylated hypoxanthine
without the need to prepare the corresponding monomers.
With ethylenediamine (NH2CH2CH2NH2). As with ammo-
nia, the production of N1-(2-aminoethyl)-hypoxanthine
containing oligomer would involve the same three steps: (i)
cleavage of the oligomer, (ii) removal of all protecting groups;
and (iii) replacement of the N-DNP group with the incoming
agent (ethylenediamine). A successful replacement (step iii)
has been demonstrated (see Scheme 1). To investigate whether
the ﬁrst two steps (cleavage and deprotection) take place as
desired, a normal pentamer (CGGAT) was treated with ethyle-
nediamine for 48 h at RT. The resulting pentamer was found
64 7 2
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Figure 2. (a) The converted modified nucleosides [N1-hydroxy-20-
deoxyinsoine 6 (Rt = 4.2 min), N1-methyl-20-deoxyinosine 4 (Rt = 10.3 min)
and 20-deoxyoxanosine 7 (Rt = 14.8 min)] can be easily separated
from the starting material 2 (Rt = 23.5 min) by HPLC. HPLC conditions:
Atlantis dC18 column (5 mm, 250 · 4.6 mm); mobile phase A was water;
mobile phase B was CH3CN; and mobile phase C was 10 mM KH2PO4,p H
6.52. The mobilephase C was kept constant at 20%, while mobile phase B was
increased from 5 to 30% over a period of 30 min. (b) These modified
nucleosides have distinct UV spectra (lmax): N1-hydroxy-20-deoxyinosine 6
(227, 252 and 294.6 nm); N1-methyl-20-deoxyinosine 4 (265 nm); 20-
deoxyoxanosine 7 (247 and 285 nm) and N1-dinitrophenyl-20-deoxyinosine
2 (245 nm) in H2O/CH3OH (1:1).
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Scheme 2. A possible, though unlikely, cleavage of the DNP group by
15NH3.
Nucleic Acids Research, 2005, Vol. 33, No. 6 1771by HPLC analysis to be exactly the same as one produced with
concentrated ammonia. This conﬁrmed that ethylenediamine
did not degrade the normal oligomers and that ethylenediam-
ine can be safely used for cleavage and deprotection (27,28).
Subsequently, the pentamer containing the versatile base
(CGXAT, X = N1-DNP-hypoxanthine) was synthesized and
treated with ethylenediamine for 48 h for the cleavage of the
oligomer, removal of the protecting groups and replacement of
N-DNP group. HPLC analysis of the resulting oligomer
showed a major peak with a retention time different from
that of the pentamer CGIAT (I = hypoxanthine). Therefore,
the modiﬁedbase inthe ethylenediamine-treatedoligomerwas
deﬁnitely not hypoxanthine. Then, the modiﬁed pentamer was
further puriﬁed by HPLC and digested with enzymes to its
nucleosides. Analysis of the enzymatic digest showed an extra
peak besides those corresponding to the four standard nucle-
osides (Figure 3). The extra peak has the same retention time
and UV spectrum as the authentic N1-(2-aminoethyl)-20-
deoxyinosine prepared by a reported protocol (20). These
data conﬁrm that our post-synthetic protocol did produce
oligomers containing N1-(2-aminoethyl)-hypoxanthine. We
have also employed this protocol for the preparation of longer
oligomers (11 and 25mer). The 11mer was used for thermo-
stability study (see below) and the 25mer will be used for
cross-linking with other macromolecules.
Thus, three different base-modiﬁed oligomers have been
prepared by post-synthetic approach using a single synthesis
and simple amino agents. We believe this procedure is of
general use.
For example, the above discussed reaction of adenine with
epoxides (such as 3,4-epoxide-1-butene), leading to enhanced
rates of deamination, results in mutagenic N1-b-hydroxyalkyl-
hypoxanthine. The current method for the preparation of
oligomers containing such N1-substituted hypoxanthine (19)
involves multiple steps. One possible solution to this
(Scheme 5) would be to use an amino equivalent of the epox-
ide, 2-amino-but-3-en-1-ol (29), to react directly with synthes-
ized oligomers containing N1-DNP-hypoxanthine in the same
manner as shown in Scheme 4. In addition, if an optically pure
enantiomer of the amine is used, the chirality should be
retained as attack of the amine at the hypoxanthine does
not affect the attached chiral carbon. Another potential
application of the post-synthetic approach would be to
make oligomers containing oxanine by reacting with
hydroxylamine followed by UV irradiation (see Scheme 1).
Oxanine is a known mutagenic product arising from the
nitrosation of guanine in DNA (24). Owing to the unstable
nature of oxanine, chemical synthesis of oligomers containing
oxanine has not been possible. The current method for the
preparation of oligomers containing oxanine has relied on
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Scheme 4. Post-synthetic conversion (R: H, Me, CH2CH2NH2).
Table 1. The meltingtemperature(Tm) valuesof normal11merDNA duplexes
and modified11merDNAduplexescontainingN1-methyl hypoxanthine(4)o r
N1-aminoethyl hypoxanthine (5)
50-CAGXAATTCGC-30
30-GTCYTTAAGCG-50
XYTm ( C) X Y Tm ( C)
G C 52.3 4 C 32.8
G T 40.6 4 T 31.5
I C 48.8 5 C 33.7
I T 40.2 5 T 32.6
Figure 3. HPLC profile of enzymatic digest of the pentamer CGXAT after the
treatmentwithethylenediamine(monitoredat260nm).PeakXhadthesameRt
andUVspectralprofileasN1-(2-aminoethyl)hypoxanthinedeoxynucleoside5.
HPLC conditions are the same as those in Figure 2a.
N
N
N
O
N
O
OH
DM DMT-O
N
N
N
O
N
O
O
DMT DMT-O
P O-CH2CH2-CN (i-Pr)2N
DNP DNP
2
DNP DNP
89
N
N
N
O
N
O
OH
HO HO
DNP DNP
i ii
(70%) (71%)
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elongation (30).
Purification and application
We have shown the production of N1-substituted hypoxanth-
ine oligomers. For structural or biological applications, it
remains crucial to ensure the obtained modiﬁed oligomers
are pure and free from their analogue oligomers, in particular,
the parent oligomer (i.e. hypoxanthine oligomer in this case).
Thus, the prepared modiﬁed oligomers require careful puri-
ﬁcation. For short-length oligomers containing modiﬁed base
(e.g. pentamers), puriﬁcation by reversed-phase HPLC is suf-
ﬁcient. But when the length of oligomers becomes longer,
reversed-phase HPLC is often inadequate to achieve good
separation. Previously, we developed a method for separation
of oligomers of identical length with one base being different
under alkaline conditions by use of Mono Q column (31).
We now demonstrate that the N1-substituted hypoxanthine
oligomers can also be well separated from their parent (hypox-
anthine) oligomers. As an example, the separation of 11mer
containing N1-(2-aminoethyl)-hypoxanthine from the same
11mer containing hypoxanthine is shown in Figure 4.
The establishment of the synthesis and puriﬁcation proto-
cols has allowed us to explore these rarely available base-
modiﬁed oligomers. As the ﬁrst attempt, we examined
base-pairing properties of these N1-substituted hypoxanthines
using melting curve measurement. Table 1 lists Tm values of
a series of complementary 11mers. Obviously, the presence of
X [either N1-methylhypoxanthine 4 or N1-(2-aminoethyl)-
hypoxanthine 5] in the duplex leads to substantially reduced
Tm values (32–33 C) compared with that (48.8 C) of the
duplex having hypoxanthine (I). It is worth noting that there
is little difference between X:C pair and X:T pair. These data
suggest that these N1-substituted hypoxanthines are likely to
disrupt Watson–Crick hydrogen bonding and probably cause
mutations.Ourﬁndingisingoodagreementwitharecentpaper
which reported a duplex containing N1-(1-hydroxy-3-butene-
2-yl)-hypoxanthinehasasharplyreducedTmvalue(33 C)(19).
Guanine has a similar structure to hypoxanthine, thus
N1-methylated guanine, if formed, would be expected to
behave similarly as N1-methylated hypoxanthine, disrupting
base pairing and inducing mutagenesis.
CONCLUSIONS
We have developed a facile method to prepare various modi-
ﬁed hypoxanthines at the nucleoside and oligomer levels by
site-speciﬁc substitution of the N-DNP group of the construc-
ted versatile base, N1-(2,4-dinitrophenyl)-hypoxanthine. The
method affords rarely available modiﬁed nucleosides and their
oligomers and should be useful for biological and structural
exploitation of N1-substituted hypoxanthine nucleosides and
their DNA. Our melting curve studies clearly indicate that
N1-substituted hypoxanthines, ifformed inDNA,wouldaffect
base pairing property and probably induce mutations.
MATERIALS AND METHODS
Chemicals and enzymes
All chemicals used on the DNA synthesizer were obtained
from Glen Research. All other chemicals and solvents, unless
2-Amino-but-3-en-1-ol
N
N
N
O
N
oligomer
DNP DNP
HO HO
NH NH2
+
N
N
N
O
N
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HO HO
* *
Scheme 5. Aproposedroutetooligomerscontainingepoxide-adductedhypoxanthine.Thechiralcentre,markedwithanasterisk,isnotinvolvedinthesubstitution.
Figure 4. Liquid chromatograms of synthetic 11mers with the sequence 50-
CAGXAATTCGC-30 (X, hypoxanthine or N1-aminoethyl hypoxanthine). The
toppanelisthepurified11mercontaininghypoxanthine,whilethemiddlepanel
is the purified 11mer containing N1-(2-aminoethyl)-hypoxanthine. The lower
panel is the co-injection of the both 11mers. Conditions: Mono Q column from
Pharmacia Biotech; Gradients of eluant A: 0.4 M NaCl and 1 mM NaOH
solution (pH 11). Gradients of eluant B: 1.2 M NaCl and 1 mM NaOH solution
(pH11).Programme:eluantBwaskeptat0%forfirst2min,andthenincreased
to 15% during the next 3 min, then to 30% during the following 20 min. Flow
rate: 1 ml/min. Monitored at 260 nm.
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chemicals and solvents were used directly without further
puriﬁcation. Nuclease P1 (Penicillium citrinum) and alkaline
phosphatase (bovine intestinal mucosa) were purchased
from Sigma.
DNA synthesizer
AnExpedite 8909(Perspective Biosystems) machinewasused
to synthesize oligomers. The manufacturer’s protocol for
phosphoramidite on 1 mmol scale was employed. Synthesized
oligomers were treated with concentrated ammonia or other
stated agents [such as
15N-labelled 5.9 M ammonia in water,
98% of isotopic purity (Cambridge Isotope Laboratories) or
ethylenediamine or methylamine (40% aqueous solution)] for
speciﬁed periods, then puriﬁed with Nensorb cartridge
(DuPont). For high purity oligomers, additional HPLC puri-
ﬁcation was generally employed.
Chromatography and instruments
Solvent systems for TLC and silica gel column chromato-
graphy were mixtures of chloroform/methanol in different
ratios: 1–5% methanol (for the DMT nucleoside product),
30–50% methanol (for N1-hydroxy-20-deoxyinosine) and
dichloromethane/ethyl acetate/Et3N (95:5:2) (for the phos-
phoramidite product). Nucleosides on TLC were identiﬁed
using p-anisaldehyde/ethanol/H2SO4 (5:90:5) solution
converting the nucleosides into black spots on heating. For
photochemical reaction, a carousel vessel was employed. The
reaction solution was irradiated with a UV lamp (400 W,
medium pressure). Other instruments used for the work are
(i) Electrothermal digital melting point apparatus; (ii) HPLC
from Waters 600S equipped with photodiode array detector
and Preparative HPLC from Waters (Delta Prep 3000) for
reversed-phase analysis and puriﬁcation; and (iii) FPLC
(Dionex BIOLC system) with Mono Q column (Pharmacia
Biotech) for the puriﬁcation of longer base-modiﬁed
oligomers. NMR instruments: 300 MHz from JOEL (JNM-
LA 300, FT NMR) and 400 MHz from JOEL (JNM-EX
400, FT NMR).
Preparation and synthesis
Preparation of N1-(2,4-dinitrophenyl)-20-deoxyinosine 2.
Compound 2 was prepared using a previously reported pro-
tocol (17). In brief, a mixture of 20-deoxyinosine (0.5 g,
1.98 mmol), K2CO3 (0.694 g, 4.95 mmol) and 1-chloro-2,4-
dinitrobenzene (0.56 g, 2.77 mmol) was suspended in anhyd-
rous DMF at 100 C for 15 min under stirring. The reaction
mixture was cooled to RT and ﬁltered, and the ﬁltrate was
dried under vacuum. The resulting solid residue was then
dissolved in acetone, adsorbed on silica gel and evaporated
to dryness. The dried material was puriﬁed by column chro-
matography eluting with chloroform/methanol (1–5%) gave
the product 2 (0.8 g, yield = 97%). Mp: 235 C (decomp.).
1H
NMR (CD3OD): (d 8.93 (dd, 1H, J = 2.55 Hz, 3H of 2,4-
dinitrophenyl), 8.79 (dd, 1H, J = 8.6, 8.6 Hz, 5H of 2,4-
dinitrophenyl), 8.63 (s, 1H, 8H), 8.46 (d, 1H, J = 4.38 Hz,
2H), 8.17 (dd, 1H, J = 8.6, 8.5 Hz, 6H of 2,4-dinitrophenyl),
6.40 (t, 1H, J = 6.6, 6.75 Hz, 10H), 4.60 (m, 1H, J = 3.0, 3.1, 6.0
Hz, 30H), 4.10 (m, 1H, J = 3.1, 5.4, 5.5 Hz, 40H), 3.82 (m, 1H,
J =5.8, 11.6 Hz, 50H),2.77 (m, 1H, J =6.6, 7.6, 13.7 Hz, 20H
a),
2.54 (m, 1H, J = 3.0, 6.5, 13.3 Hz, 20H
b).
13C NMR(CD3OD):
d 155.1 (C-6), 147.7 (C-2 of 2,4-dinitrophenyl), 147.4 (C-4 of
2,4-dinitrophenyl), 145.7(C-8), 139.9 (C-2), 133.4 (C-6 of 2,4-
dinitrophenyl), 135.1 (C-4), 145.7 (C-1 of 2,4-dinitrophenyl),
122.0 (C-5), 89.5 (C-40), 86.5 (C-10), 72.4 (C-30), 63.1 (C-50),
41.9 (C-20). MS m/z: 419 [MH
+] and 302. UV lmax: 245 nm.
Microanalysis: found, C: 45.65; H: 3.38; N: 19.33 (calculated
for C16H14O8N6: C: 45.93; H: 3.35; N: 20.09).
Synthesis of 50-O-dimethoxytrityl-N1-(2,4-dinitrophenyl)-20-
deoxyinosine 8. The prepared 2 (1 g, 2.4 mmol) was dissolved
in pyridine (16 ml) under nitrogen atmosphere. Triethylamine
(4 ml) was added dropwise. The reaction mixture was cooled
in an ice-bath. DMT–Cl (1.21 g, 3.58 mmol) was added and
the mixture stirred for  10 min. Stirring was continued at RT
for 2 h, by which time the starting material was completely
converted to a new product [by TLC, MeOH/CHCl3 (5:95)].
The reaction was quenched with 5 ml of MeOH and the
solvents evaporated under vacuum. The residue was rinsed
with hexane, ﬁltered and dried under vacuum, then puriﬁed
by column chromatography using MeOH/CHCl3 (1–5%).
While running the column, some drops of triethylamine
were added to the eluting solvents to reduce the risk of hydro-
lysis of the DMT product. The fractions containing the product
(eluting with 3–5% of MeOH in CHCl3) were pooled together
and evaporated to give the title product 8 (1.2 g, yield = 70%).
Mp: 157 C.
1H NMR (DMSO-d6): d 8.93 (d, 1H, J = 2.57 Hz,
3H of 2,4-dinitrophenyl), 8.77 (dd, 1H, J = 8.6, 8.6 Hz, 5H of
2,4-dinitrophenyl), 8.43 (s, 1H, 8H), 8.37(d, 1H, J = 4.38 Hz,
2H), 8.02 (dd, 1H, J = 8.6, 8.5 Hz, 6H of 2,4-dinitrophenyl),
6.7 to 7.7 (m, phenyl groups at 50-O-position); 6.41 (dd, 1H,
J = 6.6, 6.75 Hz, 10H), 5.55 (m, 1H, 30-OH), 4.41 (m, 1H,
J = 3.0, 3.1, 6.0 Hz, 30H), 4.10 (m, 1H, J = 3.1, 5.4, 5.5 Hz,
40H), 3.82 (m, 2H, J = 5.3, 11.6 Hz, 50H), 3.69 (2s, 6H, two
OCH3’s of DMT), 2.77 (m, 1H, J = 6.6, 7.6, 13.7 Hz, 20H
a),
2.49 (m, 1H, J = 3.0, 6.5, 13.3 Hz, 20H
b). MS m/z: 721 [MH
+],
303 and 238.
13C NMR (CD3OD) d 158.0 (C-6), 149.6 (C-2 of
2,4-dinitrophenyl), 147.5 (C-4 of 2,4-dinitrophenyl), 144.8
(C-8), 139.8 (C-2), 135.5 (C-6 of 2,4-dinitrophenyl),
129.7(C-4), 123.9 (C-1 of 2,4-dinitrophenyl), 120.8 (C-5),
155.1 (C-OCH3 of DMT group), 127.8, 123.9, 113.1 (phenyl
groups of DMT), 87.6 (C-40), 79.2 (C-10), 70.6 (C-30), 63.1
(C-50), 40.3 (C-20). HRMS (ESI) m/z: 721.2259 [M + H]
+
(calculated for C37H33O10N6: 721.2253).
Synthesis of the versatile monomer [50-O-dimethoxytrityl-N1-
(2,4-dinitrophenyl)-20-deoxyinosine-30-(O-(2-cyanoethyl)-di-
isopropylamidophosphite] 9. The above prepared 8 (100 mg,
0.13 mmol) was dissolved with anhydrous pyridine (20 ml)
and the pyridine solution was evaporated under vacuum. This
procedure was repeated twice. The residue was placed under
vacuum overnight and dissolved in dry dichloromethane
(20 ml). Then, anhydrous triethylamine (2 ml) and diisopro-
pylammonium 1H tetrazolide (125 mg, 0.73 mmol) (32,33)
were added to the solution of 8, followed by bis-
(diisopropylamino) cyanoethylphosphite (200 ml) (34). The
reaction mixture was stirred under inert atmosphere at RT
for 3 h, then mixed with NaHCO3 (20 ml) and extracted with
dichloromethane (3 · 20 ml). The combined organic layer was
dried over sodium sulfate, ﬁltered and concentrated under
vacuum. The residue was puriﬁed by column chromatography
1774 Nucleic Acids Research, 2005, Vol. 33, No. 6with CH2Cl2/EtOAc (1–5%)/Et3N (2%) to afford pure phos-
phoramidite monomer 9 (100 mg, yield = 71%).
31P NMR data
(in CDCl3): 151 and 150 p.p.m. (these two peaks represent two
stereo isomers of the phosphoramidite monomer).
Preparation of N1-
15N-20-deoxyinosine 3. Compound 2 (0.5 g,
1.20 mmol) was treated with 3 ml of aqueous
15N-NH3 (5.9 M)
(Cambridge Isotope Laboratories). The mixture was stirred at
55 C for 24 h in a sealed vial. The crude material, diluted with
10 ml of water, was ﬁltered, and the solid washed with water.
The ﬁltrate was extracted with dichloromethane. The aqueous
layer was concentrated and redissolved with MeOH/H2O (1:1)
for crystallization. Pure compound (0.21 g, yield = 70%) was
obtained. Mp: 221–224 C. UV lmax: 245 nm, MS: m/z = 254
[M + H
+].
1H NMR: (DMSO-d6) d 8.35 (s, 1H, 8H), 8.09 (d,
1H, J = 11.8 Hz, 2H), 6.34 (dd, 1H, J = 6.5, 6.7 Hz, 10H), 4.43
(m, 1H, J = 3.1, 3.2, 6.1 Hz, 30H), 3.91 (m, 1H, J = 3.2, 5.5, 5.6
Hz, 40H), 3.59 (m, 2H, J = 5.2, 11.5 Hz, 50H), 2.67 (m, 1H,
J = 6.5, 7.5, 13.6 Hz, 20H
a), 2.36 (m, 1H, J = 3.0, 6.5, 13.2 Hz,
20H
b).
13C NMR (DMSO-d6) d 158.0 (JC-N = 11.2 Hz, C-6),
149.0 (C-4), 145.8 (JC-N = 9.2 Hz, C-2), 138.5 (C-8), 125.5
(C-5), 87.9 (C-40), 83.5(C-10), 70.6 (C-30), 61.5 (C-50) 39.4
(C-20 overlapped by DMSO-d6). The data are in agreement
with the literature (20). Microanalysis: found, C:47.33; H:
4.38; N: 21.98 (calculated for C10H12O4N3
15N1: C: 47.43;
H: 4.74; N: 22.52).
Preparation of N1-methyl-20-deoxyinosine 4. Compound 2
(0.25 g, 0.59 mmol) was dissolved in 15 ml of methylamine
(40% aqueous solution) and the reaction was carried out at
55 C for 3 h. HPLC analysis of the reaction showed the start-
ing material 2 (Rt = 16.2 min) was completely converted to a
new peak 4 (Rt = 15.8 min). [HPLC conditions: Atlantis dC18
column, 5 mm, 250 · 4.6 mm. Mobile phase A: water; mobile
phase B: CH3CN; mobile phase C: 10 mM KH2PO4 (pH 6.52).
The mobile phase C was kept constant at 20%, while mobile
phaseBwaskeptat0%fortheﬁrst4min,thenincreasedto42%
over next 20 min]. Then, the reaction mixture was ﬁltered and
the ﬁltrate was evaporated to dryness, to which water (15 ml)
was added and extracted with ether (3 · 20 ml). The aqueous
layerwaslyophilizedandfurtherpuriﬁedbypreparativeHPLC
using 50% methanol in 0.2 M ammonium acetate pH 7.0 (Iso-
cratic) on Phenomenex Luna column (10 mm, 250 · 21.2 mm)
to give the product 4 (120 mg, yield = 75%). Mp: 174 C. MS
m/z: 266. UV lmax: 268 nm.
1H NMR (DMSO-d6): d 8.47
(s, 1H, 8H), 8.36 (s, 1H, 2H), 3.42 (s, 3H, N-methyl), 6.31
(1H, dd, J = 6.8, 6.8 Hz, 10H), 4.40 (m, 1H, J = 3.0, 3.1, 6.0
Hz, 30H), 4.32 (m, 1H, J = 3.0, 5.3, 5.7 Hz, 40H), 3.79 (m, 2H,
J = 5.3, 11.6 Hz, 50H), 2.68 (m, 1H, 20H
a), 2.48 (m, 1H,
20H
b).
13C NMR (DMSO-d6): 157.1 (C-6), 149.5 (C-2),
146.7 (C-4), 140.7 (C-8), 125.0 (C-5), 86.3 (C-40), 85.2
(C-10), 71.8 (C-30), 63.0 (C-50), 43.1 (C-20) and 34.6 (N-CH3).
Preparation of N1-(2-aminoethyl)-20-deoxyinosine 5. Com-
pound 2 (100 mg, 0.55 mmol) was treated with ethylenediam-
ine (3 ml) and the mixture was heated at 50 C for 4 h under
stirring. The resulting solution was dried under vacuum and
puriﬁed on preparative TLC, developed in MeOH/CHCl3/
(3:7). The band (Rf = 0.15), scratched from the plates and
eluted with MeOH/CHCl3 (1:1), afforded the title compound 5
(30 mg, yield = 33%). Mp: 114 C; UV lmax (MeOH): 251 nm;
MS m/z: 296 (M + H
+).
1H NMR (CD3OD) d 8.35 (1H, s, 8H),
8.29 (1H, s, 2H), 6.34 (1H, dd, J = 6.5, 6.5 Hz, 10H), 4.52
(1H, m, J = 3.0, 3.1, 6.0 Hz, 30H), 4.14 (2H, t, a-CH2 (i.e.
>N-CH2-), J = 6.3 Hz), 4.10 (1H, m, J = 3.0, 5.2, 5.3 Hz, 40H),
3.71(m, 2H, 50-CH2, J = 5.5, 11.3 Hz), 3.07(2H, t, J = 6.2 Hz,
b-CH2 (i.e. –CH2–NH2), 2.80 (1H, m, 20H
a), 2.46 (1H, m,
20H
b).
13C NMR (D2O): 157.9 (C-6), 149.5 (C-8), 147.6
(C-4), 141.7 (C-2), 123.2 (C-5), 86.2 (C-40), 86.1 (C-10),
71.6 (C-30), 63.2 (C-50), 42.0 (C-20) and 38.6 (CH2–NH2).
Preparation of N1-hydroxy-20-deoxyinosine 6.
(i) Via hydroxylamine hydrochloride–potassium hydroxide:
asolutionofKOH(1.2g,33.3mmol)inEtOH(10ml)was
addedtohydroxylaminehydrochloride(1.2g,17.3mmol)
inEtOH(25ml)atreflux.After10min,asolutionof2(1g,
2.4 mmol) in dry DMF (25 ml) was added to the reaction
mixture.Themixturewasheatedat80 Candmonitoredby
TLC MeOH/CHCl3(2:8). After 4h,the mixture was dried
under vacuum and treated with concentrated NH4OH
(25 ml) for 5 h. Then, the mixture was dried and purified
on silica gel column eluting with MeOH in CHCl3 with
increasing percentage of MeOH. The fractions containing
the product (eluting with 30–50% MeOH/CHCl3) were
collected and dried to give the title compound 6
(600 mg, yield = 93%).
1H NMR (D2O): d 8.37, (1H, s,
8H), 8.19 (1H, s, 2H) 6.34 (1H, dd, J = 6.6, 6.6 Hz, 10H),
4.70(m,1H,J=3.0,3.1,6.0Hz,30H),4.50(m,1H,J=3.1,
5.4, 5.5 Hz, 40H), 3.73 (m, 2H, J = 5.8, 11.6 Hz, 50H),
2.89 (m, 1H, J = 6.6, 7.6, 13.7 Hz, 20H
a), 2.60 (m, 1H,
J = 3.0, 6.5, 13.3 Hz, 20H
b).
13CN MR( D 2O): 160.0 (C-6),
149.5 (C-2), 146.7 (C-4), 140.7 (C-8), 125.0 (C-5), 88.1
(C-40),85.3(C-10),71.8(C-30),62.2(C-50)and39.8(C-20).
UV lmax = 227, 252 and 294 nm; MS m/z: 268 [M
+]. The
data are in agreement with the literature (20).
(ii) Viaaqueoushydroxylaminesolution:compound2(0.25g,
0.59 mmol) was dissolved in5ml of hydroxylamine (50%
aqueous solution)and the reaction was carried out at55 C
for 3 h. HPLC analysis of the reaction showed the starting
material 2 (Rt = 16.2 min) was completely converted to a
new peak 6 (Rt = 4.9 min). After a standard work-up pro-
cedure, the product was sufficiently pure as only a single
peak was observed by HPLC analysis. When this product
was co-chromatographed with the compound prepared by
theabove(i)protocol,HPLCgaveasinglepeak.Theyield
(from 2 to 6) was almost quantitative.
Preparation of 20-deoxyoxanosine 7.
(i) FromN1-hydroxy-20-deoxyinosine:compound6(300mg,
1.12 mmol) was dissolved in H2O (12 ml) in quartz tube.
The solution was irradiated using a UV lamp (400 W,
medium pressure, Hg arc, 150–900 nm) for 2.5 h, during
whichthereactionmixturewasmonitoredbyHPLC.Three
major peaks (Rt = 8.2, 8.7 and 9.4 min, respectively) were
observed. The crude product was isolated on preparative
HPLC on a Phenomenex Luna column (10 mm, 250 ·
21.2 mm), eluting with 10% CH3CN in 2.5 mM TEAA
(pH 5.0) and monitored at 260 nm. The peak at 9.4 min,
having the same UV profile as reported in literature (24)
for 20-deoxyoxanosine, was collected and lyophilized to
offer pure product 7 (100 mg, yield = 33%). The correct
structure was confirmed by spectral analysis (see below).
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3.7 mmol) was dissolved in 100 ml sodium acetate buffer
(3M,pH3.7),andNaNO2(10mmol,0.7g)wasaddedand
stirred at 37 C for6 h. Four major peaks (Rt= 7.4, 8.8, 9.7
and11.8min,respectively)wereobservedusingHPLCon
a Phenomenex column (synergi 4 mm, max-RP-80A,
250 · 4.6 mm). The last eluting peak, which had the
same UV profile as reported in literature (24) for 20-deox-
yoxanosine, was isolated on preparative HPLC as
described above. The product peak was collected and
freeze-dried to give 7 (100 mg, yield = 11%).
1HN M R
(DMSO-d6): d 7.94 (s, 1H, 8H), 7.89 (s, 2H, -NH2), 6.03
(dd, 1H, J = 6.7, 6.5 Hz 10H), 5.34 (br, 1H, 30-OH), 4.94
(br,1H,50-OH),4.32(m,1H,J=4.0Hz,30H),3.82(m,1H,
J = 3.6, 4.8 Hz, 40H), 3.52 (m, 2H, J = 5.8, 11.5 Hz, 50H),
2.49(m,1H,J=7.6,13.9Hz,20H
a),2.23(m,1H,20H
b).
13C
NMR(DMSO-d6):d160.0(C-6),154.6(C-2),153.2(C-8),
137.2 (C-5), 111.4 (C-4), 88.0 (C-40), 83.4 (C-10), 71.0
(C-30), 61.9 (C-50), 39.5 (C-20); UV lmax: 247 and
285 nm; MS m/z: 268 [M
+] and 152 [base fragment +1].
Stability test of 10 under the conditions for DNA synthesis. A
small amount of 30,50-diacetyl-N1-(2,4-dinitrophenyl)-20-
deoxyinosine 10 was dissolved in each of the following
DNA solutions: THF/pyridine/acetic anhydride (Capping
A), 10% N-methylimidazole in THF (Capping B), 0.02 M
iodine in THF/pyridine/water (oxidizing solution), 3% tri-
chloroacetic acid in dichloromethane (deblocking solution)
and 0.45 M tetrazole in acetonitrile (activator solution). The
reaction mixtures were monitored by TLC (MeOH/CHCl3:
1:9). There was no detectable change with compound 10
even after 2 days.
Synthesis of oligomers containing the versatile base. The oli-
gomers were synthesized on an automated DNA synthesizer
using a modiﬁed manufacturer’s standard protocol (1 mmol
scale), in which a step was introduced for manual addition of
the versatile monomer 9 (see details below). The Ultramild
monomers (Glen Research) were used for the standard phos-
phoramidite monomers, in which the bases of the monomers
are protected with base-labile protecting groups (PAC for dA,
iPr-Pac for dG and Ac for dC). The general procedure was
carried out as before (6). The portion of oligomer 30 to the
modiﬁed base was synthesized on the machine, and the ver-
satile monomer 9 was added manually. This manual addition
involves the following steps: (i) 10 mg of 9 was dissolved in
250 ml of the activator solution (0.5 M tetrazole in CH3CN);
(ii) thebottomendofthecartridge containingtheCPG-support
and partially synthesized oligomer was disconnected from
the machine; (iii) the mixture of the monomer and tetrazole
was immediately injected from a gas tight syringe; (iv) the
syringe was used to draw the solution in and out of the cart-
ridge repeatedly over a period of 5 min; and (v) the cartridge
was reconnected to the synthesizer to complete the synthesis.
Preparation of oligomer containing N1-(2-aminoethyl)-
hypoxanthine. The CPG-support bearing a pentamer
CGXAT (X = N1-DNP-hypoxanthine), with the 50-DMT
still on, was put into an Eppendorf tube, and ethylenediamine
(2 ml) was added and left at 55 C for 48 h. The desired
oligomer was separated from failure sequences and its
DMT group removed using a Nensorb cartridge (DuPont)
according to the manufacturer’s instruction. The fraction
was collected in 10 · 1 ml/tube and checked using UV spec-
trometer. The oligomer was generally located in fractions 3–5
and further puriﬁed by HPLC using a reverse-phase column
(Phenomenex, Synergi 4 mm, max-RP-80A, 250 · 4.6 mm).
Mobile phase A was water; mobile phase B was CH3CN; and
mobile phase C was 10 mM KH2PO4, pH 6.52. The mobile
phase C was kept constant at 20%, while mobile phase B was
increased from 3 to 40% over a period of 30 min. The analytes
were detected by UV absorbance at 260 nm. Nucleoside com-
position analysis was carried out as described below. A similar
preparative protocol has been successfully used for longer
oligomers (11 and 25mer) containing N1-(2-aminoethyl)-
hypoxanthine.
Preparation of oligomer containing hypoxanthine. The CPG-
support bearing the pentamer (AGXCT) [X: N1-DNP-
hypoxanthine] was treated with concentrated aqueous
ammonia (30 M) in a similar way as described above at RT
for 24 h. The resulting oligomer was puriﬁed using Nensorb
cartridge and then by HPLC as described above.
Preparation of oligomer containing N1-
15N-labelled hypox-
anthine. A pentamer (AGXCT) and a nonamer (50-CCTGXG-
GAG) [X: N1-DNP-hypoxanthine] were synthesized in a
similar way as described above and substituted and deprotec-
ted using 5.9 M
15NH3 aqueous solution at 55 C for 48 h, then
puriﬁed using a Nensorb cartridge and further puriﬁed by
HPLC. For NMR study of the nonamer, several syntheses
(on 1 mmol scale) were carried out to produce required amount
of the oligomers.
Preparation of oligomer containing N1-methylhypoxanthine.
For the preparation of oligomer containing N1-methyl-
hypoxanthine the CPG-support bearing a pentamer AGXCT
(X = N1-DNP-hypoxanthine) was treated with methylamine
(40% solution in water) at 55 C for 24 h. The oligomer was
puriﬁed on a Nensorb cartridge. HPLC analysis of the
Nensorb-puriﬁed oligomer showed a major peak of Rt = 12.9
min under the following conditions: Atlantis dC18 column,
5 mm, 250 · 4.6 mm. Mobile phase A was water; mobile
phase B was CH3CN; and mobile phase C was 10 mM
KH2PO4, pH 6.52. The mobile phase C was kept constant
at 20%, while mobile phase B was kept at 0% for the ﬁrst
4 min, then increased to 42% over next 20 min. The puriﬁed
pentamer wasdigestedanditsnucleoside compositionanalysis
was carried out as described below. The same preparative
protocol was used for the preparation of a 11mer containing
N1-methylhypoxanthine, but its puriﬁcation was carried out
using Mono Q column under alkaline conditions (pH = 11).
Nucleoside composition analysis of the
modified oligomers
After puriﬁcation by HPLC and desalting with Sep-Pac cart-
ridge(Waters),eachoftheabovepreparedmodiﬁed pentamers
was digested to its constituent nucleosides. A typical protocol
is as follows: a puriﬁed pentamer ( 0.5 OD) was dissolved in
150 ml of water, to which 25 ml of buffer (pH 4.5) and 20 mgo f
Nuclease P1 (Penicillium citrinum) were added. The mixture
was incubated at 37 C for 30 min. Then, the pH of the solution
was changed to 8 by adding a solution (pH 8) containing
600 mM of Tris–HCl and 60 mM of MgCl2, and 15 mlo f
1776 Nucleic Acids Research, 2005, Vol. 33, No. 6alkaline phosphatase (Bovine intestinal mucosa) was added
and the incubation was continued for another 30 min. [It was
noted that 20-deoxyadenosine was partially deaminated to
20-deoxyinosine when phosphodiesterase II (Bovine spleen)
was used instead of Nuclease P1]. The digest was analysed
by HPLC on a reverse-phase column (Atlantis dC18 column,
5 mm, 250 · 4.6 mm). Mobile phase A was water; mobile
phase B was CH3CN; and mobile phase C was 10 mM
KH2PO4, pH 6.52. The mobile phase C was kept constant
at 20%, while mobile phase B was increased from 5 to
30% over a period of 30 min. The analytes were detected
by UV absorbance at 260 nm. The peaks appeared in nucle-
oside composition analysis were compared with the standard
compounds (dC, dI, dG, T and dA) retention times and UV.
Retention times of standard and modiﬁed deoxynucleosides
were as follows: 6 (4.2 min); dC (5.2 min); dI (7.8 min); 5
(8.2 min); dG (8.8 min); 4 (10.3 min); T (10.5 min); and
dA (13 min).
Melting curve measurement of base-modified
oligomer duplexes
The measurements were performed in stoppered quartz
cuvettes using a UVIKON spectrophotometer connected to
a temperature control unit and a programmable heated cell
holder capable of maintaining the temperature to within
–0.1 C over a range from 25 to 90 C in a 10 mm pathlength,
500 ml quartz cell. A typical example is as follows: a pair of
11mers with complementary sequences was annealed in 0.1M
HEPES buffer (pH 7.0). The temperature-dependent change in
absorbance at 260 nm of the solution was recorded. The rate of
the temperature increase was 1 C/min. The Tm values were
determinedasthemaximumvaluesoftheﬁrstderivativegraph
of the absorbance versus temperature.
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